it`s about time, page-50

Hi Martin,

Where our resource driven market is concerned many of our exploration specs are overvalued imo whilst the exact opposite whilst the exact opposite can be said for our biotech sector.

"Only two years ago, Tamiflu was the greatest flu treatment, but now it's seen as weakening with resistence, so maybe Biota's Laninamivir (could they invent a worse name?) will probably take over in a few years after it passes FDA."

Not too familar with Biota's Laninamivir and no longer follow Biota since their big rally in 2009 re Relenza hype.

I believe the most important key to picking the right stock in this sector is to follow the trends in current events.

Population growth, Patent cliff, Big Pharma's huge cost cutting in R&D spending being replaced with license aquisitions and T/O's. Molecular biology, cellular biology and genetics are all very exciting area's of growth in this sector.

Also where Prima's CVac is concerned you should understand that we've already been granted Orphan Drug Status in both the US and Europe market which amoung many other benefits to Prima, gives us the exclusive rights to the cure or treatment for a specific condition for a period of 7 years post the approval to commercially market CVac.